DIFFMUNIZE Trademark

Trademark Overview

On Thursday, February 18, 2021, a trademark application was filed for DIFFMUNIZE with the United States Patent and Trademark Office. The USPTO has given the DIFFMUNIZE trademark a serial number of 90533923. The federal status of this trademark filing is FIFTH EXTENSION - GRANTED as of Tuesday, March 5, 2024. This trademark is owned by Pfizer Inc.. The DIFFMUNIZE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, liver disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations and smoking cessation preparations; vaccines for human use
diffmunize

General Information

Serial Number90533923
Word MarkDIFFMUNIZE
Filing DateThursday, February 18, 2021
Status734 - FIFTH EXTENSION - GRANTED
Status DateTuesday, March 5, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 10, 2021

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, liver disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations and smoking cessation preparations; vaccines for human use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, May 20, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10001-2192
Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10017

Trademark Events

Event DateEvent Description
Thursday, May 20, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, February 22, 2021NEW APPLICATION ENTERED
Thursday, July 1, 2021ASSIGNED TO EXAMINER
Tuesday, July 6, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, July 21, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 10, 2021PUBLISHED FOR OPPOSITION
Tuesday, August 10, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 5, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, March 31, 2022SOU TEAS EXTENSION RECEIVED
Thursday, March 31, 2022SOU EXTENSION 1 FILED
Thursday, March 31, 2022SOU EXTENSION 1 GRANTED
Thursday, September 22, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, April 4, 2023SOU TEAS EXTENSION RECEIVED
Saturday, April 2, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, September 20, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, September 20, 2022SOU EXTENSION 2 FILED
Tuesday, September 20, 2022SOU EXTENSION 2 GRANTED
Tuesday, April 4, 2023SOU EXTENSION 3 FILED
Tuesday, April 4, 2023SOU EXTENSION 3 GRANTED
Thursday, April 6, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, April 26, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, April 26, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, April 26, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, April 26, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, April 26, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, October 4, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, October 4, 2023SOU EXTENSION 4 FILED
Wednesday, October 4, 2023SOU EXTENSION 4 GRANTED
Friday, October 6, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, March 5, 2024SOU EXTENSION 5 GRANTED
Tuesday, March 5, 2024SOU EXTENSION 5 FILED
Tuesday, March 5, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, March 6, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Related Keywords

diffmunize preparations disorders pharmaceutical dysfunction treatment liver erectile blood viral urological